Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT04495296 is registered in ClinicalTrials.gov with Transcenta Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT04495296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 13, 2020
Completion date
September 30, 2027
Enrollment
320 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer